Continuing Education Activity
Hormone replacement therapy (HRT) is supplementing women with hormones that are lost during the menopausal transition. To relieve the symptoms associated with menopause, conventional HRT includes an estrogen and progesterone component to mimic hormones created by the human ovary. Estrogen therapies are numerous, and include those indigenous to the human ovary, for example, estradiol and estriol. Other estrogenic compounds include conjugated equine estrogen (CEE), the most commonly prescribed estrogen in the United States. They are not identical in their effect on the human body but share the same FDA indications. This activity describes the indications for hormonal replacement therapy and highlights the role of the interprofessional team in managing patients with postmenopausal symptoms.
Objectives:
Identify the different formulas of hormones for replacement therapy.
Describe the adverse effects and contraindications of hormonal replacement therapy.
Summarize the indications of hormone replacement therapy.
Explain interprofessional team strategies for improving care coordination and communication to ensure the safe use of hormonal replacement therapy and improve outcomes.
Hormone replacement therapy (HRT) is supplementing women with hormones lost during the menopausal transition. To relieve the symptoms associated with menopause,conventional HRT includes an estrogen and progesterone component to mimic hormones created by the human ovary.
Estrogen therapies are numerous, and include those indigenous to the human ovary, for example, estradiol and estriol. Other estrogenic compounds include conjugated equine estrogen (CEE), the most commonly prescribed estrogen in the United States. They are not identical in their effect on the human bodybut share the same FDA indications, according to thePhysicians Desk Reference.[1][2][3]The indicationsfor menopausal issues include:
Treatment of vasomotor symptoms of menopause
Treatment of genitourinary syndrome of menopause ( previously known as vaginal and vulvar atrophy)
Prevention of osteoporosis
A progestogen is a term used to include not only progesterone made by the human ovarybut also progesterone-like substances, also known as progestins. A woman who desires HRT andhas an intact uterusmust have a progestogen with estrogen to protect her uterus from endometrial hyperplasia or malignancy. Estrogen alone will cause the endometrial lining to grow. Progestogens stabilize the lining from proliferating abnormally. It is assumed that if a woman has had a hysterectomy that she no longer needs a progestin. Progesterone, however, is different as it can provide symptom relief from sleep disturbance and mood instability, and increasing evidence supportthat it offers tissue protection to the breast.[4][5][6]
FDA-approved indications for progestogens include:
Amenorrhea, either primary or secondary
Assisted reproductive technology treatment
Endometrial hyperplasia
Dysfunctional uterine bleeding
There arenumerous estrogen and progestogen choices, and they may be administrated orally or transdermally either through cream, patch, vaginal inserts, or subdermalpellets. Each route of administration has unique benefits and risks.
Oral Estrogen: Any estrogen administered orally results in increased activated protein-C resistance, increasing the risk of ablood clot. Oral estradiol also induces thehepatic formation of matrix metalloprotease 9, which decreases the formation and rupture of atherosclerotic plaque.
Transdermal Estrogen: Bypasses the hepatic metabolism that produces activated protein-C resistance, and the risk for blood clotting is negated.
Progestin administration is usually via the oral route, although a few are available in combination with estrogen in patch forms. Progesterone is available in an oral form that can also be used vaginally for non-FDA-approved uses.
Specializedpharmacies make compounded estrogen and progesterone creams, sublingual troches, and vaginal inserts, but these are not FDA approved and are not included in this article.
When studying the potential adverse effects of HRT, the most referenced information in the United States comes from the Women's Health Initiative (WHI).[7][8][9]
WHI Trial
This was a multifaceted trial, including two double-blind, placebo-controlled, randomized trials of postmenopausal hormone therapy.[10]
The first arm included CEE at 0.625 mg per day with medroxyprogesterone acetate (MPA) 2.5 mg per day. The second arm studied patients who had prior hysterectomies and treated with CEE 0.625 mg only.
HRT and the Breast
The CEE/MPA arm was discontinued earlier than expected due to an increased incidence of invasive breast cancer of 24% (HR=1.24). The CEE-only arm was not discontinued early, completed in 2004, and extended follow-up of patients has continued for 11.8 years. CEE use for 5 to 9 years is associated with a statistically significant reduction in breast cancer by 23% (HR=0.77). Those in the CEE arm also had decreased mortality from breast cancer by 63% compared to those not on CEE, and 38% fewer died from all other causes after breast cancer was diagnosed.
When examining evidence from European studies which usually use estradiol derivatives rather than CEE, and non-MPA progesterone or progestins, the conclusions are vastly different and unequal. Transdermal estradiol alone increased the risk of breast cancer by 10%, but estradiol with progesterone decreased the risk of breast cancer by 10%.
HRT and the Heart
In the WHI CEE/MPA arm, the overall incidence of coronary heart disease (CHD) increased by 24% over five years of use, with the most substantial elevation in risk within the first year, with an increase of 81% (HR=1.81).[11][12] This evidence requires cautious interpretation due to the following:
The average age of the patient treated in this study was 62 years. In women who started on therapy within ten years of menopause, there was a risk reduction of CAD of 11% (HR=0.89), but this was not statistically significant.
In those women who continued CEE/MPA for over six years, the risk of CAD dropped by 30% (HR=0.70).
These risks do not apply to estradiol and progesterone based treatments. Basic science studies show several mechanisms through which estradiol (not CEE) is cardioprotective. These include stabilization of atherosclerotic plaques, reduction of carotid intima-mediathickness (CIMT), and decreasing coronary artery calcium (CAC) scores. Numerous subsequent studies both in Europe and the United States show that cardiovascular disease and death are prominently reduced when HRT commences within the first four years of the menopause transition. The "Timing Hypothesis" refers to the theory that when starting HRT closer to the time of the menopausetransition, a cardiovascular benefit is seencompared with later initiation.
HRT and Risk of Stroke[13]
Stroke incidence increased in both arms of the WHI trial by 31% in the CEE/MPA arm, and 39% in the CEE arm.
Studies using oral estradiol are conflicted, showing a similar stroke risk, but the incidence of fatal stroke is unchanged.
HRT and the Risk of Venous Thromboembolism (VTE)
VTE, comprised of deep venous thrombosis and pulmonary embolism, was increased by 2-fold (HR= 2.06) in the WHI CEE/MPA arm.
Transdermal estradiol does not confer the same thromboembolic risk, as is evidenced by numerous European studies. The ESTHER study from France showed an overall risk of 0.9 for ablood clot, which is a decreased risk.[14] Subsequent studies looking at other transdermal estradiol doses and routes confirm these findings, with at least a null effect for blood-clotting risk.
Contraindications for oral or transdermal estrogen-based therapies include:
Known, suspected, or history of breast cancer
Known or suspected history of other estrogen-basedcancer, i.e., uterine cancer. Women who have had a hysterectomy and have no remaining evidence of disease are still candidates for HRT
Activedeep venous thrombosis (DVT) or a history of DVT or pulmonary embolism (PE)
History of blood clotting disorder, the most common being Factor V Leiden mutation carriers
Active or history of arterial thrombotic diseases such as myocardial infarction or stroke
Chronic liver disease or dysfunction
Migraine with aura
These contraindications do not apply to transvaginal based estrogen therapies, as the serum concentration of estrogen from this route is extremely low. The North American Menopause Society (NAMS) has recommended that the black-box warning that applies to conventional HRT not be applied to transvaginal estrogen treatments.
Hormone levels of estradiol and progesterone are not traditionally measured for monitoring purposes. Instead, the relief of menopausal symptoms and the absence of adverse effects signify an adequate medical response.
Adverse side effects may include:
No scientific evidence links HRT with significant weight gain.
HRT, including androgen therapies such as testosterone, should be monitored with serum testingbut is not considered conventional HRT.
Patients undergoing menopause require management from an interprofessional team that also includes the pharmacist and nurse. To improve patient outcomes, clinicians should not empirically prescribe hormone replacement therapy. These hormones correlate with a variety of adverse effects, including an increased risk of breast cancer, stroke, heart disease, and deep vein thrombosis. The duration of treatment of these hormones should not be more than a few years, and close monitoring is required. If the female has mild symptoms of menopause, then education should be provided about the benefits and harm of these hormones. The pharmacist should consult with the prescriber on the exact agent and dosing, while also examining the patient's medication record. Nursing needs to be very aware of signs of adverse events, and monitor closely on subsequent visits, alerting the clinician of any concerns. This interprofessional team approach will drive the best outcomes with HRT. [Level 5]
Link:
Hormone Replacement Therapy - StatPearls - NCBI Bookshelf
- Pharmac seeking bids from suppliers to fund another type of hormone replacement therapy - New Zealand Doctor Online - April 5th, 2024
- What is Hormone Replacement Therapy and how safe is it? - PinkNews - March 19th, 2024
- Menopausal Hormone Therapy | Johns Hopkins Medicine - January 6th, 2024
- Find a Provider - Biote - January 6th, 2024
- Biote Certified Providers By State - Biote - January 6th, 2024
- Is Hormone Replacement Therapy Right for You? What to Know - Motherly Inc. - January 6th, 2024
- Natural hormone replacement therapy: How it works - Medical News Today - February 6th, 2023
- Hormone replacement therapy (HRT) - Types - NHS - December 27th, 2022
- Helping Reduce Your Risk of Breast Cancer ThedaCare - ThedaCare - October 13th, 2022
- 'How Hormone Replacement Therapy Impacted My Strength Training' - Women's Health - October 13th, 2022
- This Simple Blood Test Gives Incredible Insights Into Building Muscle Mass - Yardbarker - October 13th, 2022
- Take strides to raise awareness of breast cancer - Theredstonerocket - October 13th, 2022
- Breast cancer and hormone therapy | GNP online - brytfmonline.com - October 13th, 2022
- Early detection matters | Marshall Medical employee recounts her breast cancer journey - Sand Mountain Reporter - October 13th, 2022
- Hormone replacement therapy (HRT) - Benefits and risks - NHS - October 4th, 2022
- Thyroid Hormone Replacement Therapy | Johns Hopkins Medicine - October 4th, 2022
- Prescribing HRT in women with migraine The Medical Republic - The Medical Republic - October 4th, 2022
- Caring for the gynecologic needs of the adolescent patient - Contemporary Obgyn - October 4th, 2022
- Im a GP heres the best way to treat acne and when to see a doctor... - The US Sun - October 4th, 2022
- State-by-state prevalence of the 5 most common types of cancer - KFOR Oklahoma City - October 4th, 2022
- How Menopause Affects Cholesterol And What to Do About It - TIME - September 25th, 2022
- Stroke symptoms in men & women - Times of India - September 25th, 2022
- Turn back the clock with collaborative care solutions Peace Arch News - Peace Arch News - September 25th, 2022
- Health benefits of flaxseed - Punch Newspapers - September 25th, 2022
- Progesterone Market Size to Grow by USD 1.23 Billion, Rise in Research and Development of Progesterone Drugs -Technavio - Yahoo Finance - September 25th, 2022
- Hormone Replacement Therapy for Menopause - Healthline - September 16th, 2022
- Hormone Replacement Therapy Market to Hit Value of $29.65 Billion by 2028 | Looming Shortage HRT Products to be a Key Challenge - GlobeNewswire - September 16th, 2022
- This Is How Long It Takes For Hormone Replacement Therapy To Start Working - Health Digest - September 16th, 2022
- Progesterone to be fully funded for all who need it in 'a welcome change' - Stuff - September 16th, 2022
- Contributor: In the Misdiagnosis of Menopause, What Needs to Change? - AJMC.com Managed Markets Network - September 16th, 2022
- Premenstrual syndrome: Real-life impact and coping strategies - Medical News Today - September 16th, 2022
- Why you should be paying attention to Ohio Supreme Court races - News 5 Cleveland WEWS - September 16th, 2022
- When You Take Vitamin C Every Day, Here's What Happens Eat This Not That - Eat This, Not That - September 16th, 2022
- Using HRT (Hormone Replacement Therapy) - breast cancer - September 8th, 2022
- Bioidentical Hormone Replacement Therapy for Men - September 8th, 2022
- Hormone Replacement Therapy for Over 60s | Gransnet - September 8th, 2022
- Rethinking "The Change": Discover 40+ Ways to Embrace Menopause - PR Newswire - September 8th, 2022
- Seven days in medicine: 31 Aug to 6 Sep 2022 - The BMJ - September 8th, 2022
- If Covid Distorted Your Sense Of Time, Don't Panic: You're In The Majority - Kaiser Health News - September 8th, 2022
- Hot Flashes Can Impact Up to 80% of Women So Why Arent We Talking About It? - SheKnows - August 30th, 2022
- Woman shares the frustrations of going through menopause at age 49 - Insider - August 30th, 2022
- F*cking Ridiculous! Scotland Is Championing Menopause But Got One Big Thing Wrong - Suggest - August 30th, 2022
- Hunter Schafer Criticized For Appearing to Agree With Anti-Nonbinary Post - Newsweek - August 30th, 2022
- Gender Dysphoria Is Now Protected Under the Americans With Disabilities Act and It's a Pretty... - POPSUGAR - August 30th, 2022
- Boxing New Zealand supports open category in Olympic style boxing - New Zealand Herald - August 30th, 2022
- Doylestown Turns The Town Teal For Ovarian Cancer Awareness Month - Patch - August 30th, 2022
- The far right aims to eliminate trans people But the working... - Liberation - August 30th, 2022
- Hormone Replacement Therapy Will Be Available Over-The-Counter In The UK In SeptemberWe Wish The U.S. Would Follow Suit - Suggest - August 22nd, 2022
- To Your Good Health: Length of hormone treatment depends on the individual - Agri-News - August 22nd, 2022
- Menopause: Symptoms, causes, complications, diagnosis and treatment - Rising Kashmir - August 22nd, 2022
- How to Treat and Prevent Melasma with Nutrition - Intelligent Living - August 22nd, 2022
- How to eat and exercise for menopause: why you should prep now - Stylist Magazine - August 22nd, 2022
- 4 Real-Life Dating Tips for People Living with Alopecia - Everyday Health - August 22nd, 2022
- Cardiovascular health in the menopause transition: a longitudinal study of up to 3892 women with up to four repeated measures of risk factors - BMC... - August 22nd, 2022
- Hormone replacement therapy (HRT) | Health Navigator NZ - July 3rd, 2022
- Hormone-replacement therapy: current thinking - PubMed - July 3rd, 2022
- With 6.1 % CAGR, Hormone Replacement Therapy Market Size worth USD 21.49 billion by 2028 Industry Trends - Benzinga - July 3rd, 2022
- Lower Hormone Levels Linked to Risk of Sleep Apnea - Medscape - July 3rd, 2022
- Menopause and Sensitive Teeth: Symptoms, Causes, Treatments - Healthline - July 3rd, 2022
- 8 Bad Habits Leading to Breast Cancer Eat This Not That - Eat This, Not That - July 3rd, 2022
- Open, honest conversations key in reducing LGBTQ health disparities - WFYI - July 3rd, 2022
- Stopping Hormone Replacement Therapy: Cold Turkey Menopause - Breastcancer.org - July 3rd, 2022
- What the Reversal of Roe Means for the LGBTQ+ Community - Progressive.org - July 3rd, 2022
- Top 10 Hormone Replacement Therapy Industry to Look Out for in 2022 by Abbott Laboratories, Novartis, Pfizer, Inc., Mylan Laboratories - Digital... - June 22nd, 2022
- University of Medicine and Health Sciences to Host "LGBTQ+ Medicine & Theory: Providing Compassionate Care" - Yahoo Finance - June 22nd, 2022
- International Yoga Day: Womens health & yoga - Times of India - June 22nd, 2022
- Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer - Yahoo Finance - June 22nd, 2022
- 7 Strong Buy Dividend Aristocrats Are Safe-Haven Stocks to Own During a Recession - 24/7 Wall St. - June 22nd, 2022
- Hormone-Replacement Therapy Is Life-Changing: What to Consider Before Getting Started - POPSUGAR - June 13th, 2022
- High Doses of Widely-Used Cancer Drug in Hormonal Therapy Can Increase Risk of Brain Tumour in Women by Seven Times | The Weather Channel - Articles... - June 13th, 2022
- Latest study reveals that two male contraceptive pills could expand options for birth control - Interesting Engineering - June 13th, 2022
- Pride Week: Beginning Hormone Replacement Therapy : Short Wave - NPR - June 13th, 2022
- The heartbreak, hope and courage of a Maine transgender child - The Maine Monitor - June 13th, 2022
- Trans conversion therapy: What to expect when MPs debate ban - Open Democracy - June 13th, 2022
- If the menopause movement is to be truly revolutionary, it needs to include women with cancer - iNews - June 4th, 2022
- The Very Peri Summit Resource Centre: Hormone Replacement Therapy with Dr Yasmin Tan. - Mamamia - June 4th, 2022
- Finding the "Sweet Spot": Thyroid Hormone Treatment and Cardiovascular Disease - Endocrinology Network - June 4th, 2022
- Rethinking Identity and Testosterone in Imagine a Body - The New Yorker - June 4th, 2022
- Postmenopausal Years Are Creative and Satisfying for Women - Oprah Mag - June 4th, 2022
- Medroxyprogesterone Acetate Market by Type (Oral, Parenteral), Application (Contraceptive, Hormone Replacement Therapy, Treatment of Endometriosis,... - May 15th, 2022